Journal of Clinical Oncology
Articles in this Issue
Assessment of infection risk factors and related complications in newly diagnosed multiple myeloma: A retrospective cohort analysis.
e19533 Background: Patients with newly diagnosed multiple myeloma (NDMM) are at risk of developing early infections within 3-6 months, contributing signif...
Metastatic site pattern as predictor of outcome of first-line alternating oxaliplatin-based chemotherapy and nivolumab for patients with microsatellite-stable (MSS) colorectal cancer (CRC).
3533 Background: The randomized METIMMOX trial evaluated short-course oxaliplatin-based chemotherapy (FLOX) alternating with nivolumab for previously untr...
Impact of incorporating APPs on enrollment and engagement in NCI trials at an NCORP site.
e23039 Background: Oncology care increasingly relies on multiple team members to deliver high quality care. Clinical trials are integral to advancing the...
Longitudinal ctDNA monitoring for post-surgical molecular residual disease in patients with stage I-IIIb melanoma.
9571 Background: Circulating tumor DNA (ctDNA) has emerged as an important biomarker for early recurrence detection and monitoring disease status in patie...
Sintilimab plus oxaliplatin and capecitabine versus sintilimab plus albumin-bound paclitaxel and capecitabine for advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma patients: A prospective, randomized, open-label, investigator-initiated phase 2 trial.
e16042 Background: The treatment options for locally advanced unresectable GEJ adenocarcinoma are still limited in China. Sintilimab is a PD1 mAb, previou...
Outcomes of odronextamab in non-Hodgkin lymphoma: A systematic review and meta-analysis.
e19006 Background: Emerging therapeutic strategies for Non-Hodgkin Lymphoma (NHL) include bispecific antibodies like odronextamab, a CD20×CD3 agent that d...
A phase I study to assess the safety of adjuvant natural killer cell injection in combination with standard treatment in patients with radical pancreatectomy.
e14534 Background: Adjuvant chemotherapy for six months is recommended for patients who have undergone radical pancreatectomy, regardless of stage. The ob...
Exploring access barriers for patients with uterine malignancies: Results from a single-center analysis.
e13507 Background: Uterine cancer typically presents with early symptomatic bleeding; delayed presentation can result in diagnosis at an advanced stage wi...
Investigating the association between peak post-infusion absolute lymphocyte count (ALC) and delayed toxicity in myeloma (MM) patients (pts) receiving cilta-cel.
7522 Background: Movement and neurocognitive treatment emergent adverse events (MNTs), cranial nerve palsies (CNPs) and immune-effector cell enterocolitis...
TeliMET NSCLC-04: A phase 2, open-label, randomized, global study of 2 telisotuzumab vedotin regimens in patients with previously treated c-Met protein–overexpressing, locally advanced/metastatic non-squamous <i>EGFR</i> wildtype non-small cell lung cancer.
TPS8658 Background: c-Met protein (also known as MET protein) overexpression is observed in ∼25% of patients with non-squamous EGFR...
Cardiovascular and oncologic outcomes of nivolumab + ipilimumab vs. pembrolizumab in malignant melanoma: A global real-world data analysis.
e21538 Background: Malignant melanoma is a highly aggressive cancer often treated with immune checkpoint inhibitors. While nivolumab + ipilimumab and pemb...
Diffusing capacity for carbon monoxide (DLCO) change and outcome in advanced non-small cell lung cancer (aNSCLC) treated with immune checkpoint inhibitors (ICIs).
e20602 Background: Despite recent therapeutic advances, identifying effective prognostic markers in aNSCLC remains an unmet need. DLC) has shown prognosti...
Shifts in the landscape of colorectal cancer burden: A systematic analysis using the global burden of disease and SEER databases.
e15699 Background: Colorectal cancer (CRC) is the third most diagnosed cancer and the second leading cause of cancer-related deaths worldwide. However, th...
MYC amplification and protein expression as prognostic markers in pediatric and young adult osteosarcoma.
10043 Background: Risk stratification in osteosarcoma relies on metastatic status and tumor necrosis after chemotherapy. D...
A real-world analysis of the effectiveness of pembrolizumab by type of associated treatment in patients with metastatic cervical cancer: Added value of bevacizumab.
5531 Background: Pembrolizumab (pembro) showed a statistical significant survival benefit in persistent, recurrent, or metastatic cervical cancer (CC) whe...
Gut-associated checkpoint as a prognostic biomarker in metastatic renal cell carcinoma (mRCC): Results from a randomized first-line clinical trial.
4512 Background: The gut microbiota modulates anti-cancer immune response and therefore benefit to immune checkpoint inhibitors (ICIs). Gut dysbiosis impa...
Barriers to guideline concordant cancer care for patients with limited english proficiency: A mixed methods study.
e13842 Background: Approximately 25 million people in the United States have limited English proficiency (LEP), posing challenges in communication and dis...
First-line rilvegostomig (rilve) plus chemotherapy (CTx) in advanced biliary tract cancer (BTC): Primary analysis of GEMINI-Hepatobiliary substudy 2 Cohort A.
4080 Background: Immune checkpoint inhibitors plus CTx have improved outcomes in first-line advanced BTC (median progression-free survival [PFS] 6.5–7.2 m...
Matching-adjusted indirect comparison of bireociclib plus fulvestrant versus abemaciclib plus fulvestrant as second-line treatment of HR+/HER2− advanced breast cancer.
e15141 Background: Abemaciclib plus fulvestrant has demonstrated significant clinical benefit in patients with hormone receptor-positive (HR+), human epid...
Impact of early imaging-based screening on outcomes in young patients with von Hippel-Lindau disease: A retrospective study.
e22506 Background: Von Hippel-Lindau (VHL) disease is a hereditary condition predisposing individuals to multisystem tumor development. Early detection an...
Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study.
7036 Background: First-line ibrutinib (Ibr) + venetoclax (Ven) treatment for CLL/SLL was tested in the phase 2 CAPTIVATE study, including minimal residual...
Lurbinectedin with immunotherapy in extensive-stage small cell lung cancer: Current insights and future prospects—A systematic review.
e20100 Background: Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive malignancy with limited treatment options and a poor prognosis. Combi...
Effectiveness of rituximab plus chemotherapy in pediatric Burkitt lymphoma: A systematic review and meta-analysis.
e22006 Background: Burkitt lymphoma is an aggressive non-Hodgkin lymphoma originating from mature B cells. This meta-analysis aims to assess the efficacy...
Comprehensive precise CAR-T bridging therapy for diffuse large B-cell lymphoma: A multicenter study from the Chinese Southwest Study Group.
7027 Background: Chimeric antigen receptor T-cell (CAR-T) therapy has showed substantial efficacy in relapsed/refractory diffuse large B-cell lymphoma (r/...
Evaluating the impact of physical activity on survival outcomes in cancer patients.
e22610 Background: Emerging evidence suggests that physical activity may play a pivotal role in improving survival outcomes among cancer patients. However...